Gazyva: Phase III data

The open-label, international Phase III GOYA trial in 1,418 previously untreated patients with CD20-positive DLBCL showed that 1,000 mg IV Gazyva every 3 weeks for 24

Read the full 262 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE